Valuation: EyePoint, Inc.

Market Cap 32.31M 28.85M 26.47M 24.08M 45.15M 3.06B 46.05M 316M 127M 1.61B 121M 119M 5.1B P/E 2026 *
-0.1x
P/E 2027 * -0.19x
Enterprise Value -298M -266M -244M -222M -417M -28.25B -425M -2.92B -1.18B -14.91B -1.12B -1.1B -47.1B EV / Sales 2026 *
-175x
EV / Sales 2027 * -46.1x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: EyePoint, Inc.

1 day+7.58%
1 week+2.49%
Current month+7.58%
1 month-88.47%
3 months-96.94%
6 months-97.19%
Current year-97.95%
1 week 0.34
Extreme 0.3446
0.42
1 month 0.34
Extreme 0.3446
3.57
Current year 0.34
Extreme 0.3446
18.87
1 year 0.34
Extreme 0.3446
19.11
3 years 0.34
Extreme 0.3446
30.99
5 years 0.34
Extreme 0.3446
30.99
10 years 0.34
Extreme 0.3446
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Others

Chief Financial Officer

-139,906 0.1669%
18/8/26 Buy

Director

10,600 0.0126%
10/7/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+7.58%+2.49%-97.14%-94.86% 32.31M
-0.46%+10.31%+63.52%+143.15% 1,257B
-0.97%+1.60%+43.25%+80.09% 651B
-2.05%+0.73%+32.47%+101.62% 510B
-0.19%-0.53%+52.95%+67.29% 388B
-0.78%+5.51%+72.55%+44.25% 366B
+0.64%+2.86%+33.13%+58.94% 303B
+0.01%+8.24%+12.25%+35.13% 288B
-0.12%+4.68%+55.97%+74.59% 252B
-0.21%+7.34%+42.19%+109.69% 211B
Average +0.62%+4.38%+31.11%+61.99% 422.67B
Weighted average by Cap. -0.33%+5.30%+49.27%+93.73%

Financials

2026 *2027 *
Net sales 1.7M 1.52M 1.4M 1.27M 2.38M 161M 2.43M 16.66M 6.72M 85.09M 6.39M 6.25M 269M 3.85M 3.44M 3.15M 2.87M 5.38M 364M 5.49M 37.67M 15.18M 192M 14.45M 14.14M 608M
Net income -325M -290M -266M -242M -454M -30.79B -463M -3.18B -1.28B -16.25B -1.22B -1.19B -51.33B -198M -177M -162M -148M -277M -18.77B -283M -1.94B -782M -9.91B -744M -728M -31.29B
Net Debt -331M -295M -271M -246M -462M -31.31B -471M -3.24B -1.3B -16.53B -1.24B -1.21B -52.2B -210M -187M -172M -156M -293M -19.86B -299M -2.05B -828M -10.48B -787M -771M -33.11B
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
02/11/26 US$0.3748 +7.58% 6,327,727
30/10/26 US$0.3484 -8.32% 6,119,164
29/10/26 US$0.3800 +0.69% 6,601,723
28/10/26 US$0.3774 +3.91% 6,504,012
27/10/26 US$0.3632 -0.68% 9,675,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.3748USD
Average target price
8.438USD
Spread / Average Target
+2,151.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - EyePoint, Inc.
  1. Stock Market
  2. Stocks
  3. EYPT Stock